WallStSmart

Auna S.A. (AUNA)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 1190% more annual revenue ($56.58B vs $4.39B). NVS leads profitability with a 23.9% profit margin vs 2.2%. AUNA trades at a lower P/E of 13.7x. NVS earns a higher WallStSmart Score of 51/100 (C-).

AUNA

Hold

48

out of 100

Grade: D+

Growth: 5.3Profit: 5.0Value: 6.0Quality: 3.0
Piotroski: 4/9Altman Z: 0.92

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AUNA.

NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AUNA2 strengths · Avg: 9.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

P/E RatioValuation
13.7x8/10

Attractively priced relative to earnings

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

AUNA4 concerns · Avg: 2.8/10
Market CapQuality
$375.47M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
6.5%3/10

ROE of 6.5% — below average capital efficiency

Profit MarginProfitability
2.2%3/10

2.2% margin — thin

EPS GrowthGrowth
-50.9%2/10

Earnings declined 50.9%

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : AUNA

The strongest argument for AUNA centers on Price/Book, P/E Ratio.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : AUNA

The primary concerns for AUNA are Market Cap, Return on Equity, Profit Margin. Debt-to-equity of 2.23 is elevated, increasing financial risk. Thin 2.2% margins leave little buffer for downturns.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Key Dynamics to Monitor

AUNA profiles as a value stock while NVS is a declining play — different risk/reward profiles.

AUNA carries more volatility with a beta of 1.64 — expect wider price swings.

AUNA is growing revenue faster at 6.5% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 48/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Auna S.A.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Auna S.A. is a prominent telecommunications and digital services provider in Latin America, specializing in integrated solutions that enhance connectivity and customer experience. With a comprehensive portfolio that includes high-speed internet, television, and mobile services, Auna caters to both residential and business clients across a variety of markets. The company's dedication to innovation and exceptional customer service has established it as a key player in the region's dynamic digital landscape. Its extensive and robust infrastructure positions Auna favorably to leverage the growing demand for advanced telecom solutions, presenting significant growth opportunities for institutional investors.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?